The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...

Investors should continue to retain this Zacks Rank #3 (Hold) stock in their portfolio as it appears to have significant ...

Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Erie Indemnity Co. (ERIE) on Thursday reported profit of $174.7 million in its second quarter. The Erie, Pennsylvania-based company said it had profit of $3.34 per share.

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...

MBIA Inc. MBI) on Wednesday reported a loss of $56 million in its second quarter. On a per-share basis, the Purchase, New ...

NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.

Amgen AMGN reported second-quarter 2025 adjusted earnings of $6.02 per share, which beat the Zacks Consensus Estimate of ...

Novo Nordisk A/S (NVO) on Wednesday reported second-quarter profit of $4.03 billion. On a per-share basis, the Bagsvaerd, ...